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ABSTRACT
Introduction Refractory asthma represents a signiﬁcant
unmet clinical need where the evidence base for the
assessment and therapeutic management is limited. The
British Thoracic Society (BTS) Difﬁcult Asthma Network
has established an online National Registry to
standardise specialist UK difﬁcult asthma services and to
facilitate research into the assessment and clinical
management of difﬁcult asthma.
Methods Data from 382 well characterised patients,
who fulﬁlled the American Thoracic Society deﬁnition for
refractory asthma attending four specialist UK
centresdRoyal Brompton Hospital, London, Glenﬁeld
Hospital, Leicester, University Hospital of South
Manchester and Belfast City Hospitaldwere used to
compare patient demographics, disease characteristics
and healthcare utilisation.
Results Many demographic variables including gender,
ethnicity and smoking prevalence were similar in UK
centres and consistent with other published cohorts of
refractory asthma. However, multiple demographic
factors such as employment, family history, atopy
prevalence, lung function, rates of hospital admission/
unscheduled healthcare visits and medication usage
were different from published data and signiﬁcantly
different between UK centres. General linear modelling
with unscheduled healthcare visits, rescue oral steroids
and hospital admissions as dependent variables all
identiﬁed a signiﬁcant association with clinical centre;
different associations were identiﬁed when centre was
not included as a factor.
Conclusion Whilst there are similarities in UK patients
with refractory asthma consistent with other comparable
published cohorts, there are also differences, which may
reﬂect different patient populations. These differences in
important population characteristics were also identiﬁed
within different UK specialist centres. Pooling multicentre
data on subjects with refractory asthma may miss
important differences and potentially confound attempts
to phenotype this population.
INTRODUCTION
Patients with difﬁcult asthma (persistent symp-
toms and/or frequent exacerbations despite treat-
ment at step 4/5 of British Thoracic Society (BTS)
management guidelines
1) represent a signiﬁcant
unmet clinical need
23 ; however, the evidence base
for the assessment and management of this group
of patients is small.
14
In 2006, the BTS Research Committee together
with physicians with a specialist interest in difﬁ-
cult asthma established a National Registry for
dedicated UK Difﬁcult Asthma Services. The aims
were to standardise specialist clinical services, to
further deﬁne and characterise clinical phenotypes
in subjects with well characterised severe asthma
and to facilitate research into the assessment and
clinical management of difﬁcult asthma.
Observational studies have suggested that after
detailed systematic evaluation, w50% of patients
referred with difﬁcult to control asthma do not
have refractory disease, but have multiple other
mechanisms for persistent symptoms
5e7 The
National Registry includes UK centres operating
established dedicated multidisciplinary assessment
protocols to ensure identiﬁcation of patients with
well characterised refractory asthma. The aim of
this paper is to describe the clinical features of
a well characterised UK refractory asthma popula-
tion from the National Difﬁcult Asthma Registry
and compare patient groups from individual
centres.
METHODS
There are currently seven UK dedicated Specialist
Difﬁcult Asthma Services submitting data to the
UK Registry, but the data presented in this paper
are from the four pilot UK centresdRoyal
Brompton Hospital, London, Glenﬁeld Hospital,
Leicester, University Hospital of South Manchester
and Belfast City Hospital.
The Registry is hosted online by Dendrite Clin-
ical Systems and admits password-protected
anonymised data, after fully informed written
consent; individual centre data can be downloaded
locally by registered users for audit purposes.
Subjects were entered into the Registry in a non-
selected manner, and centres were asked to have
100 subjects entered by a predeﬁned deadline. The
data in this manuscript were utilised as part of an
initial service evaluation between clinical centres,
and represent subjects, who after detailed assess-
ment, fulﬁlled the American Thoracic Society
(ATS) deﬁnition of refractory asthma.
8
Statistical analysis
Anonymised data were analysed using Statistical
Package for Social Sciences (SPSS, Chicago, Illinois,
USA), Version 16. Between-centre comparisons
were made using one-way analysis of variance
(ANOVA) and KruksaleWallis testing, with
posthoc comparisons using Bonferroni and
GameseHowell comparisons, as appropriate. For
categorical variables, comparisons were made using
c
2 analysis with exact tests as appropriate. As
multiple between-centre comparisons were made,
statistical signiﬁcance was taken as p<0.01 to
minimise the number of results exhibiting type 1
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Asthmaerror. General linear modelling was used to generate models with
the dependent variables unscheduled care visits, rescue oral
steroids and hospital admissions (entered as the square root of
the index variable to ensure residuals in the model were
normally distributed). For intensive care unit (ICU) admission,
only 71 of 376 cases had prior ICU admission, so a binary logistic
regression model was used. In all modelling, ﬁnal model selection
was parsimonious, with accepted variables having statistical
signiﬁcance of p<0.05.
RESULTS
Group data and between-centre comparisons are shown in
tables 1e6.
Demographics
There was a predominance of females, and more ethnic white
Caucasians in all centres (table 1). In three of the centres w1/3
of subjects were in full-time employment, but this was signiﬁ-
cantly higher in Leicester (58.2%). Patients were less likely to
record asthma as the reason for not working in Belfast,
compared with Manchester and London, which had similar
prevalences of full-time employment.
A family history of asthma was more common in Belfast and
an atopic history highest in London (71.7%); there were also
signiﬁcant between-centre differences in the recorded prevalence
of perennial rhinitis and seasonal rhinitis (table 2). Subjects in
Belfast and London were more likely to have had prior nasal
surgery compared with Leicester and Manchester. Of note, few
premenopausal women recorded signiﬁcant premenstrual
asthma worsening.
Atopy
The higher atopic prevalence in London was supported by
allergen testing (table 3), with greater inhalant allergen sensiti-
sation compared with Belfast (Leicester and Manchester use
a clinically targeted allergen testing approach). The higher
London atopic prevalence was not explained by younger ‘age of
asthma onset’, because in subjects with asthma diagnosis
$10 years, allergic sensitisation remained higher (eg, house dust
mite-positive subjects: Belfast, 18 of 59 (30.5%) vs London, 38 of
41 (92.7%)).
Healthcare utilisation
In terms of healthcare utilisation, unscheduled visits (deﬁned as
general practitioner (GP)/hospital unscheduled contact) were
higher in Belfast compared with other centres (table 4). Pre-
referral rescue steroid courses were lower in Manchester,
although the hospital admission rate was highest in London, as
was prior admission to an ICU.
Medication
The number of subjects taking maintenance oral steroids was
highest in London, though the median dose was not different
between centres (table 4). Inhaled steroid dose was signiﬁcantly
higher in London compared with other centres, and patients
were more likely to be receiving theophyllines in London and
leukotriene receptor antagonists in London and Belfast. There
was a range of nebuliser usage, but again this was highest in
London (66%) and lowest in Leicester (24%). Few patients were
on anti-immunoglobulin E (IgE) treatment or steroid-sparing
Table 1 Patient demographic data
All (382) Belfast (95) Brompton (99) Leicester (79) Manchester (109)
Female (%) 241 (63.1) 56 (58.9) 63 (63.6) 45 (57.8) 77 (70.6) p¼0.259
Race, n (%)
White 346 (90.6) 95 (100) 82 (82.8) 64 (81.0) 105 (96.3) p<0.001
Asian 24 (6.3) 0 9 (9.1) 15 (19.0) 0
African 10 (2.6) 0 7 (7.1) 0 3 (2.8)
Unknown 4 (1.0) 0 1 (1.0) 0 3 (2.8)
Age at ﬁrst assessment at Difﬁcult
Asthma Service (n)
44.9613.7 (381) 43.2614.4 (95) 43.0613.1 (99) 45.7613.6 (78) 47.5613.4 (109) p¼0.055
Age (years) at diagnosis of asthma (n) 17 (3e35) (377) 20 (2e39) (95) 10 (2e27) (99) 25 (5e43) (79) 18 (4.25e33) (104) p¼0.019
Height, m (n) 1.6660.096 (382) 1.6560.09 (95) 1.6861.0 (99) 1.6660.11 (79) 1.6561.0 (109) p¼0.118
Weight, kg (n) 81.2619.9 (374) 81.3619.8 (95) 83.8618.3 (99) 81.8623.1 (71) 78.3619.2 (109) p¼0.254
BMI (n) 28 (24.3e32.4) (374) 28 (25e34) (95) 30 (25e32) (99) 28.4 (24.4e34.5) (71) 27 (24e31) (109) p¼0.291
Smoking status
Never 233 (61.0) 57 (60.0) 69 (69.7) 50 (63.3) 57 (52.3) p¼0.182
Ex-smoker (years since stopped) 114 (29.8) (8.9768.15) 27 (28.4) (11.069.92) 25 (25.2) (9.6466.72) 24 (30.4) (10.3568.26) 38 (34.9) (5.5566.35)
Current smoker (%) (pack-years) 22 (5.8) (16.12611.62) 9 (9.5) (16.8613.4) 2 (2.0) (9.0611.3) 5 (6.3) (16.4615.6) 6 (5.5) (18.268.01)
Unknown 13 (3.4) 2 (2.1) 3 (3.0) 0 8 (7.3)
Working status
Full time (%) 151 (39.5) 34 (35.8) 33 (33.3) 46 (58.2) 38 (34.9) p<0.001
Asthma-related not working (%) 100 (26.2) 16 (16.8) 40 (40.4) 9 (11.4) 35 (32.1)
Other cause for not working (%) 104 (27.2) 39 (41.0) 15 (15.2) 22 (27.8) 28 (25.7)
Part-time working due to asthma (%) 12 (3.1) 0 (0) 10 (10.1) 0 2 (1.8)
Part-time working due to other cause
(%)
10 (2.6) 2 (2.1) 1 (1.0) 1 (1.3) 6 (5.5)
Unknown 5 (1.3) 4 (4.2) 0 (0) 1 (1.3) 0
Work-related worsening of asthma (%) p¼0.98
Yes 19 (5.0) 4 (4.2) 5 (5.0) 4 (5.1) 6 (5.5)
No 354 (92.7) 89 (93.7) 94 (95.0) 69 (87.3) 102 (93.6)
Not recorded 9 (2.3) 2 (2.1) 0 6 (7.6) 1 (0.9)
Group data (mean6SD or median (IQR)) for all subjects are presented in column 2 followed by data for individual centres. Between-centre comparisons for continuous variables were made
using one-way analysis of variance or KruksaleWallis test (for posthoc comparisons, see text) and for categorical variables using c
2 exact testing.
Signiﬁcance was taken as p<0.01.
BMI, body mass index.
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Asthmamedication at referral (three Manchester patients on omali-
zumab had started in a clinical trial before referral).
Lung function
Prebronchodilator forced expiratory volume in 1 s (FEV1) for all
subjects and degree of airﬂow obstruction was similar in
Manchester, London and Belfast; FEV1 was signiﬁcantly higher
and less obstructive in Leicester (table 5). In those subjects
where a postbronchodilator study was available, again
prebronchodilator spirometry was signiﬁcantly better in
Leicester compared with other centres, and postbronchodilator
FEV1 was signiﬁcantly better in Leicester compared with Belfast.
Residual volume and total lung capacity were signiﬁcantly
greater in London compared with Belfast and Manchester, but
KCO (carbon monoxide transfer coefﬁcient) was normal and
similar in all centres.
When lung function was compared between smoking groups,
only KCO was different (never smokers 105.8616.7, ex-smokers
97.6619.4, current smokers 94.7621.5); posthoc testing
conﬁrmed that KCO was lower in ex-smokers compared with
never smokers (p¼0.020).
Inﬂammatory markers, immunoglobulins and bone densitometry
The baseline blood eosinophil count was higher in Belfast
compared with other centres, and posthoc testing conﬁrmed that
this difference was restricted to a difference between Belfast and
London. Induced sputum, fractional exhaled nitric oxide (FeNO)
andIgEshowednosigniﬁcantdifferencesbetweencentres(table6).
General linear modelling
General linear models with dependent variables of unscheduled
care visits, rescue oral steroids and hospital admission are shown
in table 7. For prior ICU admission, binary logistic regression
Table 2 Medical history
All (382) Belfast (95) Brompton (99) Leicester (79) Manchester (109)
Family history of asthma (%)
Yes 193 (50.5) 70 (73.7) 44 (44.4) 33 (41.8) 46 (42.2) p<0.001
No 168 (44.0) 24 (25.3) 54 (54.5) 33 (41.8) 57 (52.3)
Missing 21 (5.5) 1 (1.0) 1 (1.0) 13 (16.4) 6 (5.5)
Family history of asthma death (%)
Yes 12 (3.1) 5 (5.3) 3 (3.0) 0 4 (3.7) p¼0.439
No 175 (45.8) 63 (66.3) 40 (40.4) 31 (39.2) 41 (37.6)
Not recorded 195 (51.0) 27 (28.4) 56 (56.6) 48 (60.8) 66 (58.7)
Prior history of atopy (%)
Yes 219 (57.3) 58 (61.1) 71 (71.7) 48 (60.8) 42 (38.5) p<0.001
No 159 (41.6) 37 (38.9) 28 (28.3) 31 (39.2) 63 (57.8)
Missing 4 (1.1) 0 0 0 4 (3.7)
Perennial rhinitis (%)
Yes 111 (29.0) 44 (46.3) 35 (35.4) 17 (21.5) 15 (13.8) p<0.001
No 261 (68.3) 50 (52.6) 63 (63.5) 62 (78.5) 86 (78.9)
Missing 10 (2.6) 1 (1.0) 1 (1.0) 0 8 (7.3)
Seasonal rhinitis (%)
Yes 140 (36.6) 29 (30.5) 48 (48.5) 35 (44.3) 28 (25.7) p<0.001
No 231 (60.5) 65 (68.4) 50 (50.5) 44 (55.7) 72 (66.1)
Missing 11 (2.9) 1 (1.0) 1 (1.0) 0 9 (8.2)
Eczema (%)
Yes 103 (27.0) 27 (28.4) 28 (28.3) 24 (30.4) 24 (22.0) p¼0.77
No 270 (70.7) 68 (71.6) 70 (70.7) 55 (69.6) 77 (70.6)
Missing 9 (2.4) 0 1 (1.0) 0 8 (7.3)
Other atopic condition (%) (food hypersensitvity, anaphylaxis, etc.)
Yes 53 (13.9) 17 (17.9) 8 (8.1) 20 (25.3) 8 (8.1) p¼0.002
No 320 (83.8) 78 (82.1) 90 (90.9) 59 (74.7) 93 (84.7)
Missing 9 (2.4) 0 1 (1.0) 0 8 (7.2)
Prior nasal surgery (%)
Yes 55 (14.4) 20 (21.1) 20 (20.2) 8 (10.1) 7 (6.4) p¼0.009
No 316 (82.7) 75 (78.9) 78 (78.8) 70 (88.6) 93 (85.3)
Missing 11 (2.9) 0 1 (1.0) 1 (1.3) 9 (8.3)
Nasal polyps (%)
Yes 51 (13.4) 13 (13.7) 13 (13.1) 12 (15.2) 13 (11.9) p¼0.98
No 321 (84.0) 82 (86.3) 85 (85.9) 67 (84.8) 87 (79.8)
Missing 10 (2.6) 0 (0) 1 (1.0) 0 9 (8.3)
History of oesophageal reﬂux (%)
Yes 158 (41.4) 56 (58.9) 44 (44.4) 24 (30.4) 34 (31.2) p<0.001
No 214 (56.0) 39 (41.1) 54 (54.5) 54 (68.4) 67 (61.5)
Missing 10 (2.6) 0 1 (1.0) 1 (1.3) 8 (7.3)
Prior OGD (%) 17 (3.7) 6 (6.3) 5 (5.0) 4 (5.1) 2 (1.8) p¼0.51
Prior pH proﬁle (abnormal proﬁle) 36 (19) 13 (6) 19 (11) 1 (0) 3 (2) p¼0.62
Signiﬁcant catamennial asthma (%) 16 of 188 women (8.5) 4 of 41 (9.8) 5 of 55 (9.1) 2 of 34 (5.9) 5 of 58 (8.6) p¼0.939
Group data, n (%) for all subjects, are presented in column 2 followed by data for individual centres. Between-centre comparisons were made using c
2 exact testing.
Signiﬁcance was taken as p<0.01.
OGD, oesophagogastroduodenoscopy.
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Asthmamodelling with ever ICU admission as dependent variable
demonstrated signiﬁcant associations with age of asthma diag-
nosis (OR 0.965 (95% CI 0.948 to 0.984), p<0.001) and inhaled
steroid dose per 100 mg increase in beclomethasone dipropronate
(BDP) equivalent (OR 1.029 (95% CI, 1.003 to 1.055), p<0.05).
DISCUSSION
This UK Difﬁcult Asthma Network aims to standardise clinical
assessment across specialist centres and use a Registry to facil-
itate phenotypic characterisation and research in patients with
‘difﬁcult asthma’. These specialist centres have established
assessment protocols, ensuring subjects have well characterised
refractory asthma. The numbers of subjects per centre provide
further analytical strengths and, when data are consistent across
three or four centres, we believe they are representative of the
UK refractory asthma population. Between-centre differences
are not explained by local referral patterns (60e75% tertiary
referrals, the remainder coming from primary/non-specialist
physicians); however, this cannot be entirely excluded.
Three other multicentre studies have collated data on‘difﬁcult
asthma’ previously. The TENOR study was a large-scale US
observational study (4756 patients, 3489 adults) of difﬁcult
asthma ($2 unscheduled care visits or $2 oral steroid bursts plus
high dose inhaled steroids)
9; 51% were classiﬁed as severe asthma
by the treating physician. The ENFUMOSAcross-sectional study
(12 centres in nine European countries) recruited 163 patients
with severe asthma ($1 exacerbation in the previous year despite
$1200 mg of BDP equivalent inhaled steroid).
10 The SARP study
included 204 subjects $12 years, fulﬁlling the ATS deﬁnition of
refractory asthma (9 US and 1 UK centre).
11 In these studies,
groupdataonlyarepresented,whereasourdataadditionallyallow
comparison between individual UK centres, which has demon-
strated important differences.
Our data conﬁrm the usual female preponderance which
remains unexplained,
9e11 though catamennial asthma was not
a common exacerbating factor.
Ageatﬁrstassessmentwassimilarbetweencentres,thoughage
at asthma diagnosis was signiﬁcantly lower in the Brompton
Table 3 Allergen testing
All (382) Belfast (95) Brompton (99) Leicester (79) Manchester (109)
Environmental allergen test (%)
RAST only 98 (25.6) 9 (9.5) 13 (13.1) 7 (8.9) 69 (63.3)
SPT only 36 (9.4) 5 (5.2) 4 (4.0) 18 (22.8) 9 (8.2)
Both 226 (59.2) 81 (85.3) 79 (79.8) 50 (63.3) 16 (14.7)
Not done 22 (5.8) 0 3 (3.0) 4 (5.1) 15 (13.8)
Domestic exposures (%) pets
Yes (%) 116 (30.4) 27 (28.4) 20 (20.2) 29 (36.7) 40 (36.7) p¼0.026
No (%) 253 (66.2) 64 (67.3) 77 (77.8) 50 (63.2) 62 (56.9)
Not recorded (%) 13 (3.4) 4 (4.2) 2 (2.0) 0 7 (9.7)
Aspergillus/fungi
Yes (%) 18 (4.7) 1 (1.0) 0 4 (5.1) 13 (11.9) p<0.001
No (%) 351 (91.9) 91 (95.8) 97 (98.0) 74 (93.7) 89 (81.7)
Not recorded (%) 13 (3.4) 3 (3.2) 2 (2.0) 1 (1.3) 7 (6.4)
House dust mite (%)*
Positive 181 (47.4) 34 (35.8) 85 (85.9) 33 (41.8) 29 (26.6) p<0.001
Negative 74 (19.4) 61 (64.2) 3 (3.0) 1 (1.3) 9 (8.3)
Not done 127 (33.2) 0 11 (11.1) 45 (57.0) 71 (65.1)
% positivity for patients tested 71.0% 35.8% 96.6% 97.0% 76.3%
Cat (%)*
Positive 159 (41.6) 29 (30.5) 77 (77.8) 18 (22.8) 35 (32.1) p<0.001
Negative 84 (22.0) 66 (69.5) 7 (7.1) 1 (1.3) 10 (9.2)
Not done 139 (36.4) 0 15 (15.1) 60 (75.9) 64 (58.7)
% positivity for patients tested 65.4% 30.5% 91.7% 94.7% 77.8%
Dog (%)*
Positive 155 (40.6) 26 (27.4) 78 (78.8) 23 (29.1) 28 (25.7) p<0.001
Negative 95 (24.9) 68 (71.6) 7 (7.1) 1 (1.3) 19 (17.4)
Not done 132 (34.5) 1 (1.0) 14 (14.1) 55 (69.6) 62 (56.9)
% positivity for patients tested 62.0% 27.7% 91.8% 95.8% 59.6%
Mixed grasses (%)*
Positive 149 (39.0) 31 (32.6) 77 (77.8) 26 (32.9) 15 (13.8) p<0.001
Negative 81 (21.2) 64 (67.4) 5 (5.0) 1 (1.3) 11 (10.1)
Not done 152 (39.8) 0 (0) 17 (17.2) 52 (65.8) 83 (76.1)
% positivity for patients tested 64.8% 32.6% 93.9% 96.3% 57.7%
Aspergillus (%)*
Positive 170 (44.5) 18 (18.9) 76 (76.8) 14 (17.7) 62 (56.9) p<0.001
Negative 99 (25.6) 68 (71.6) 6 (6.1) 2 (2.5) 23 (21.1)
Missing 113 (29.6) 9 (9.5) 17 (17.2) 63 (79.7) 24 (22.0)
% positivity for patients tested 63.2% 20.9% 92.7% 87.5% 72.9%
Group data, n (%) for all subjects, are presented in column 2 followed by data for individual centres. Exposure to Aspergillus/fungi refers to these being apparent away from normal domestic
areas (eg, windows, bathroom, etc.) Between-centre comparisons were made using c
2 exact analysis.
Signiﬁcance was taken as p<0.01.
RAST, radioallergosorbent; SPT, skin prick testing.
*The data presented are for subjects with either a positive RAST or skin prick test.
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Asthmacohort. Median body mass index (BMI) was in the non-obese
range, and similar to that seen in TENOR (average BMI was
29.9),
9 whereas the average BMI in ENFUMOSAwas lower (male
average26.5,femaleaverage27.2).Currentsmokingisinfrequent,
though 29.8% had previously been smokers, with no difference
between centres; these smoking prevalence ﬁgures are similar to
Table 4 Healthcare utilisation and medication
All (382) Belfast (95) Brompton (99) Leicester (79) Manchester (109)
Unscheduled visits in
preceding 12 months (n)
4( 2 e6) (372) 5 (2e9) (91) 4 (1e6) (99) 4 (2e6) (79) 3 (2e5) (103) p¼0.007
Rescue steroid courses in
the previous year (n)
4( 2 e6) (352) 5 (1e6) (84) 5 (2.75e7) (86) 4 (2e6) (79) 2 (0e4) (103) p<0.001
Hospital admissions in
preceding 12 months (n)
0( 0 e2) (377) 0 (0e1) (93) 1 (0e3) (99) 0 (0e1) (79) 0 (0e1) (106) p<0.001
Total number of ICU admission
(range) (n)
0 Range (0e11) (379) 0 Range (0e4) (95) 0 Range (0e11) (99) 0 Range (0e1) (79) 0 Range (0e10) (106) p¼0.012
Maintenance oral steroids (%) 158 of 379 (41.7) 32 of 95 (33.7) 57 of 98 (58.2) 30 of 79 (38.0) 39 of 107 (36.4) p¼0.002
Oral steroid dose (mg) (n) 15 (10e20) (154) 13 (6e20) (31) 15 (10e20) (57) 10 (7.5e15) (30) 15 (10e30) (36) p¼0.021
BDP equivalent dose (mg) (n) 2000 (1000e2000) (362) 1800 (1000e2000)m (93) 2000 (2000e2000) (94) 2000 (1600e2000) (78) 1500 (1000e2000) (97) p<0.001
SABA use per day 6 (4e8) (262) 8 (4e10) (31) 4 (6e8) (75) 4 (2e6) (62) 8 (4.75e10) (94) p¼0.001
Theophylline (n) 146 of 375 (37.9) 40 of 95 (42.1%) 52 of 97 (53.6%) 25 of 77 (32.5%) 29 of 106 (27.4%) p¼0.001
Nebuliser use (%) 165 of 376 (43.9) 45 of 94 (47.9) 64 of 97 (66.0) 19 of 79 (24.0) 37 of 106 (34.9) p<0.001
Steroid-sparing meds
None 7 of 372 91 95 78 101 p¼0.361
Methotrexate (1.9) 1 0 0 3
Ciclosporin 0 1 1 0
Azathioprine 0 0 0 1
Anti-IgE treatment 3 of 378 (0.8) 0 0 0 3 p¼0.054
PPI (%) 111 of 360 (29.7) 28 of 95 (29.5) 32 of 97 (32.9) 18 of 79 (22.8) 33 of 107 (30.8) p¼0.498
Aspirin/NSAID sensitivity (%) 36 of 378 (9.5) 8 of 93 (8.6) 8 of 92 (8.7) 10 of 76 (13.2) 10 of 105 (9.5) p¼0.741
Antihistamine (%) 89 of 374 (23.8) 17 of 94 (18.1) 26 of 96 (27.1) 16 of 78 (20.5) 30 of 106 (28.3) p¼0.271
Nasal steroids (%) 96 of 374 (25.7) 27 of 94 (28.7) 24 of 96 (25.0) 17 of 78 (21.8) 28 of 106 (26.4) p¼0.77
Leukotriene receptor
antagonists (%)
141 of 375 (37.6) 52 of 94 (55.3) 42 of 96 (43.8) 25 of 79 (31.6) 22 of 106 (20.8) P<0.001
Group data (mean6SD or median (IQR) unless stated otherwise) for all subjects are presented in column 2 followed by data for individual centres. Between-centre comparisons for continuous
variables were made using one-way analysis of variance or KruksaleWallis test (for posthoc comparisons, see text) and for categorical variables using c
2 exact testing.
Signiﬁcance was taken as p<0.01.
BDP, beclomethasone dipropronate; ICU, intensive care unit; IgE, immunoglobulin E; NSAID, non-steroidal anti-inﬂammatory drug; PPI, proton pump inhibitor; SABA, short-acting b-agonist.
Table 5 Lung function
All (382) Belfast (95) Brompton (99) Leicester (79) Manchester (109)
Prebronchodilator spirometry (n) FEV1 (litres)
% predicted
(371) (95) (96) (77) (103)
1.9460.81 1.9260.70 1.8660.078 2.2160.86 1.8460.87 p¼0.013
65.9623.6 65.7624.0 60.4620.4 75.3622.8 64.7625.0 p¼0.001
FVC (litres) % predicted 3.0761.01 3.0760.87 3.2661.07 3.1161.10 2.9061.00 p¼0.081
81.9619.8 82.5620.2 82.4620.4 83.1621.1 79.1619.6 p¼0.424
FEV1/FVC ratio % 63.1615.2 62.7614.8 56.2614.5 71.1613.3 63.4614.8 p<0.001
Subjects with baseline postbronchodilator
study (n)
(261) (62) (43) (75) (81)
Prebronchodilator FEV1 (litres) (% predicted) 1.9060.83 1.6960.63 1.8360.80 2.2260.87 1.8160.87 p¼0.001
(64.0623.1) (56.9618.6) (58.6620.5) (75.4623.0) (62.7624.3) p<0.001
Prebronchodilator FVC (litres) (% predicted) 3.0561.05 2.9960.94 3.3661.15 3.1161.10 2.8961.02 p¼0.128
p¼0.220
(80.6619.8) (79.0619.3) (84.1618.1) (83.3621.4) (77.8619.3)
Postbronchodilator FEV1 (litres) (% predicted) p¼0.020
2.1860.88 1.9360.70 2.2961.03 2.3660.86 2.1460.89 p¼0.004
(73.6624.2) (65.3621.4) (73.6626.3) (80.7622.5) (74.2624.7)
Postbronchodilator FVC (litres) (% predicted) p¼0.246
3.2961.06 3.2160.97 3.6061.26 3.3061.11 3.2360.95 p¼0.664
(87.4619.1) (85.2619.9) (90.9621.1) (87.8620.3) (87.4616.4)
Postbronchodilator FEV1/FVC ratio (%) p<0.001
65.0614.6 60.6612.4 61.44615.82 71.6612.3 65.0615.6
Total lung capacity % predicted (n) 104.9616.8 (265) 107.8617.8 (80) 109.1613.9 (96) 98.0616.6 (89) p<0.001
Residual volume % predicted (n) 134.4642.0 (263) 127.8644.2 (80) 151.0640.1 (97) 121.8635.9 (86) p<0.001
KCO % predicted (n) 101.5617.5 (256) 97.3617.7 (79) 98.0613.8 (94) 110.04618.5 (83) p<0.001
Group data (mean6SD) for all subjects are presented in column 2 followed by data for individual centres. Between-centre comparisons for continuous variables were made using one-way
analysis of variance (for posthoc comparisons, see text).
Signiﬁcance was taken as p<0.01.
FEV1, forced expiratory volume in 1 s. FVC, forced vital capacity, KCO, carbon monoxide transfer coefﬁcient.
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AsthmatheTENORcohortwhere4.3%of ‘difﬁculttocontrol’adultswere
current smokers, 32% ex-smokers and 63.7% never smokers.
9
In Leicester, more patients were in full-time employment,
compared with 33e36% in other centres, but why asthma is less
often volunteered as thereason for notworking in Belfastremains
unclear, though this would signiﬁcantly impact on costing refrac-
tory asthma. Occupational asthma worsening was consistently
uncommon, and only appears relevant to a minority of patients.
Three centres recorded a family history of asthma in 42e44%,
but in Belfast this was 74%. Retrospective data checking
Table 6 Blood testing and bone density
All (382) Belfast (95) Brompton (99) Leicester (79) Manchester (‘109)
Blood eosinophil count 310
9/l (n) 0.30 0.34 0.1 0.12 0.24 p¼0.001
(0.25e11.0) (0.19e0.72) (0.2e0.5) (0.35e0.58) (0.08e0.54)
(360) (94) (98) (72) (96)
Percentage sputum eosinophil count (n) 3.0 6.0 3.45 1.0 p¼0.159
(0.25e11.25) (3e9) (0.07e17.12) (0e11.0)
(123) (31) (56) (36)
FeNO ppb (n) 34.5 40 30.5 34 p¼0.321
(16e65) (17e92) (14e65) (12e60)
(133) (57) (24) (52)
IgE kU/l (n) 130 113 166.5 126 140 p¼0.831
(53.5e292) (60e256) (51.5e299.5) (50e335.5) (51e280)
(349) (93) (96) (77) (83)
IgG g/l (n) 9.3 9.15 9.1 9.85 p¼0.052
(7.85e10.9) (7.9e10.0) (7.0e10.0) (8.1e11.77)
(195) (86) (63) (46)
IgA g/l (n) 1.9 1.9 2.1 1.8 p¼0.275
(1.5e2.7) (1.48e2.72) (1.7e2.7) (1.21e2.58)
(195) (86) (63) (46)
IgM g/l (n) 1.0 1.0 1.1 1.1 p¼0.588
(0.8e1.4) (0.7e1.4) (0.88e1.4) (0.72e1.42)
(195) (86) (63) (46)
Bone density (T scores) *(n) (169) (41) (70) (58)
L1eL4  0.6461.42  0.8161.15  0.5461.34  0.6761.67 p¼0.603
Femoral neck  0.2661.20  0.2260.84  0.0761.28  0.6161.19 p¼0.017
*18 (10.6%) subjects had either a spinal or femoral neck bone density less than or equal to  2.5 (osteoporosis) and 58 (34.3%) subjects had a spinal or femoral neck bone density less than or
equal to  1.0 (osteopenia).
Group data (mean6SD or median (range)) for all subjects are presented in column 2 followed by data for individual centres. Between-centre comparisons for continuous variables were made
using one-way aanalysis of variance or KruksaleWallis test (for posthoc comparisons, see text) and for categorical variables using c
2 analysis.
Signiﬁcance was taken as p<0.01.
FeNO, fractional exhaled nitric oxide; Ig, immunoglobulin.
Table 7 General linear models for listed dependent variables: dependent variables were entered as the square root of the index variable to ensure
residuals in the model were normally distributed
Dependent variable Factors/co-variates Regression coefﬁcients (95% CI) p Value
Hospital admission in 12 months prior to
clinical assessment
Unscheduled visits in prior 12 months 0.051 (0.033 to 0.071) p<0.001
Total number of prior intensive care
admissions
0.086 (0.012 to 0.16) p<0.05
Hospital centre Belfast  0.108 ( 0.341 to 0.126) p<0.001
Brompton 0.418 (0.187 to 0.650)
Leicester 0.077 ( 0.160 to 0.314)
Manchester 0
On theophylline at initial assessment 0.192 (0.017 to 0.366) p<0.05
Rescue steroids in 12 months prior to
clinical assessment
Hospital centre Belfast 0.588 (0.295 to 0.881) p<0.001
Brompton 0.784 (0.490 to 1.078)
Leicester 0.757 (0.458 to 1.055)
Manchester 0
Blood eosinophils at ﬁrst assessment 0.238 (0.105 to 0.372) p<0.001
Age at ﬁrst assessment at Difﬁcult
Asthma Service
 0.001 ( 0.019 to  0.003) p<0.01
Nebuliser usage at initial assessment 0.223 (0.004 to 0.443) p<0.05
Unscheduled visits in 12 months prior to
clinical assessment
Age at ﬁrst assessment at difﬁcult asthma
service
 0.011 ( 0.019 to  0.003) p<0.01
Hospital centre Belfast 0.500 (0.188 to 0.813) p<0.01
Brompton 0.148 ( 0.159 to 0.454)
Leicester 0.418 ( 0.090 to 0.746)
Manchester 0
Gender 0.284 (0.051 to 0.518) p<0.05
Blood eosinophils at ﬁrst assessment 0.147 (0.003 to 0.290) p<0.05
792 Thorax 2010;65:787e794. doi:10.1136/thx.2010.137414
Asthmaconﬁrmed that the ‘family history’ deﬁnition was applied
consistently, and a family history appears more common in
Northern Ireland, which has traditionally low levels of immi-
gration. Recorded familial asthma death was low, suggesting it is
an infrequent event, even in this refractory group; however, this
was not well recorded and we cannot exclude that the familial
asthma death rate may be higher.
This higher reported atopic prevalence in London was
supported by allergen testing (table 3), as subjects were more
likely to be allergen positive. The difference is particularly
notable between London and Belfast, where all subjects were
tested for similar allergens. In Leicester and Manchester, targeted
allergen testing is performed, and reported allergen positivity
may represent an underestimation. Interestingly, Apergillus
sensitivity in Manchester (which is routinely tested) was
‘between’ that of London and Belfast. In SARP, 71% of those
with severe asthma were skin prick positive to $1 of 14 aller-
gens (85% and 87% for subjects with mild/moderate asthma,
respectively).
11 In ENFUMOSA, w58% of those with severe
asthma had positivity $1 allergen, (well controlled asthmatics
w76%), with individual allergen positivity in those with severe
asthma varying between w10% and 35%.
10 Individual centre
data are not presented in these studies; however, our data
suggest that individual allergen sensitisation appears to vary in
different refractory asthma populations in UK specialist centres,
possibly reﬂecting important regional differences even within
the UK.
Oral steroid courses in the 12 months before referral were
fewer in Manchester compared with other centres, where the
median number of rescue steroids was 4e5 per annum; this
difference may reﬂect patient recollection in Manchester, but the
similarity in other centres supports signiﬁcant rescue steroid use
in this group. In SARP, 54% of those with severe asthma
reported $3 steroid bursts per year
11 and, in our cohort, 63%
used $3 courses in the previous year. Unscheduled visits were
more common in Belfast, although hospital admissions and ICU
usage were higher in London, though they were uncommon
events. In SARP, 54% reported $1 unscheduled care visit per
year,
11 whereas this was 86% for this UK cohort. It is unclear if
differences are due to different healthcare delivery for exacer-
bation management, or to differences in exacerbation severity.
Almost twice as many patients in the Brompton were on
maintenance steroids, compared with the other centres. Inhaled
steroid dose at referral was also higher in the Brompton patients
compared with all other centres. The UK cohort average inhaled
steroid dose was similar to the ENFUMOSA severe asthma
cohort (16766667 mg BDP equivalent), but comparative data
between centres were not presented. Our data suggest that in
multicentre studies specifying a minimum steroid dose for
inclusion, it is important to examine medication utilisation from
individual centres.
Wide variation was noted in nebuliser usage, and patients in
Belfast and Brompton were more likely to be on a theophylline
and leukotriene receptor antagonist at referral. These differences
presumably relate to local prescribing practice and referral
pattern, but all patients were on multiple medications at
referral. Few patients were on steroid-sparing medication or anti-
IgE treatment at referral, suggesting that these medications are
not widely used outside specialist centres.
We observed a low prevalence of aspirin/non-steroidal anti-
inﬂammatory drug (NSAID) sensitivity and, while different
deﬁnitions of aspirin sensitivity probably affect reported preva-
lence,
12 our data are notably different from those of ENFU-
MOSA, which suggested an association between asthma
severity and self-reported aspirin exacerbation.
10 Our data are
similarly based on self-reported increased asthma symptoms
after aspirin/NSAID ingestion, and the difference may reﬂect
differences between the UK and a European population.
Spirometry for the UK group was lower than for the ENFU-
MOSA study (FEV1 % predicted 71.8% rising to 80.9% post-
bronchodilator), though it was similar to SARP (FEV1 %
predicted 62622%), consistent with a patient population with
more severe asthma. Consistent with better spirometry in
ENFUMOSA, total lung capacity in the UK cohort was higher
(134.7642.3%), compared with ENFUMOSA (104.4615.2%).
Of note, KCO was normal and similar in all centres despite the
high prevalence of ex-smoking in the UK cohort, though we
demonstrated a relationship between KCO and prior smoking.
The normal percentage KCO is again different from ENFU-
MOSA, where KCO was 90.6619% predicted; the authors
suggested that abnormal gas exchange and parenchymal injury
may be a feature of severe asthma. However, our data suggest
that in a well characterised population with refractory asthma,
the transfer factor is well preserved, and any reductions relate to
prior smoking history.
Interesting differences between UK centres are seen for
spirometry. Prebronchodilator and postbronchodilator spirom-
etry and degree of airﬂow obstruction were better in Leicester
compared with other centres. Allied with other indicesdfor
example, increased numbers in full-time workdit suggests less
severe disease in the Leicester cohort compared with other
centres. This is despite the fact that all of these patients fulﬁlled
the same deﬁnition of refractory asthma, suggesting a spectrum
of severity using the ATS deﬁnition. Prospective analysis of
patient outcome and treatment requirements, which is facili-
tated by the UK Registry, will help address this issue further.
Residual volume % predicted and total lung capacity were
signiﬁcantly greater in the London cohort compared with Belfast
and Manchester; however, the absolute differences are small.
Peripheral blood eosinophil count was highest in Belfast, but
there was no signiﬁcant difference in sputum eosinophilia or
FeNO between centres. In SARP, FeNO data were available on
135 subjects with severe asthma and FeNO was 40638 ppb,
which is similar to this UK cohort. Mean IgE in ENFUMOSA
was 109 (95% CI 85 to 139), and in SARP 10065.75. We have
presented IgE as median (IQR) as this is not normally distrib-
uted in this cohort, but our median value of 130 is comparable
with other published cohorts. In subjects who had bone density
measurements, 18 (10.6%) subjects had either a spinal or femoral
neck bone density T score less than or equal to  2.5 (osteopo-
rosis) and 58 (34.3%) subjects had a Tscore less than or equal to
 1.0 (osteopenia). Bone density measurements were not done in
all subjects and there may be some selection bias; however, these
data are consistent with a signiﬁcant morbidity in this group.
Important clinical outcomes in this group are unscheduled
healthcare visits, rescue steroid use, hospital admission and ICU
admission. Hierarchical regression modelling supported impor-
tant between-centre differences, as this remained a signiﬁcant
factor in the ﬁnal model for three of the four tested dependent
variables (table 7). It is important to note that if this patient
group was treated as a homogeneous study population, different
regression models were obtained, with other additional signiﬁ-
cant associations, which were not demonstrated when centre
was included as a factor (data not shown). Importantly,
however, the factors which remained in our regression models
with clinical centre included as a random factor also remained in
each regression model, independent of whether centre was
included or not.
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AsthmaThe association between peripheral blood eosinophils and
both steroid exposure and unscheduled visits in this refractory
patient group is consistent with other studies which have
demonstrated a relationship between blood and/or sputum
eosinophilia and asthma exacerbation and loss of asthma
control.
13e15 Patients who were younger at the time of assess-
ment at the Difﬁcult Asthma Service had higher levels of both
unscheduled visits and hospital admissions in the respective
models. The association between total number of prior ICU
admissions and hospital admission is perhaps not surprising as
prior severe asthmatic events are associated with increased risk
of asthma death.
16 17 Home nebuliser usage and theophylline
prescription may also be markers of severity and thus related to
increased rescue steroid exposure and unscheduled visits,
respectively. The association with female gender and unsched-
uled visits is interesting, particularly as this gender effect is not
translated into either more steroid exposure or hospital admis-
sion, and might suggest a lower threshold for healthcare contact
in females. The association between dose of inhaled steroids and
ICU admission is interesting, particularly as this has previously
been shown to be a predictor of treatment-resistant asthma
5 and
is presumably an index of longer term severity with increasing
doses of inhaled steroid over time. The association with age of
asthma diagnosis may reﬂect ICU admission in childhood but,
even if this is the case, it does suggest that severe asthma in this
group is present from an early stage after the initial diagnosis.
Insummary,this paperpresents fortheﬁrst time demographic,
physiological and immunological data from a well characterised
UK population of subjects with refractory asthma. While simi-
larities exist to other comparable published cohorts, there are also
differences which may reﬂect different patient populations
(difﬁcult to control vs refractory vs different levels of asthma
severity), and again argues for the production and application of
precise deﬁnitions for this population of subjects with asthma. In
addition, important population characteristics are different
between UK specialist centres, suggesting that ‘grouping’ multi-
centre data (even centres in the same country) may miss impor-
tant differences and potentially confound attempts to phenotype
refractory asthma, giving rise to so-called ‘ecological fallacy’. The
differences identiﬁed between UK centres warrant further study,
butsuggestrefractoryasthmamaybemoreheterogeneouswithin
an individual country than previously known.
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